Product Information
PRAMIPEXOLE 0.125 MG TABLET is a generic product labeled by ScieGen Pharmaceuticals Inc., priced at $0.0394 per EA under NDC 50228012610. Its NADAC has been published 273 times since Jul 14, 2021.
FDA first approved this application on Oct 28, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.125 mg/1
Manufacturer
ScieGen Pharmaceuticals Inc.NDC
50228012610
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PRAMIPEXOLE DIHYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA203855FDA Approved
10/28/2014
TE Code
AB
On Market Since
10/29/2014
Pharmacological Classes
Price Statistics
The NADAC for PRAMIPEXOLE 0.125 MG TABLET has been published 273 times since Jul 14, 2021, and over the history we have for it it has declined 25.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0394 per EA |
|---|---|
| All-time high | $0.0595 (Jan 12, 2022) |
| All-time low | $0.0350 (Nov 20, 2024) |
| 52-week high | $0.0425 |
| 52-week low | $0.0394 |
| Median price | $0.0467 |
| Average price | $0.0474 |
| Largest weekly change | +23.8% (Aug 21, 2024) |
| Weeks tracked | 273 |
| Tracking since | Jul 14, 2021 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ScieGen Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Pramipexole Dihydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonergot Dopamine Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PRAMIPEXOLE 0.125 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PRAMIPEXOLE 0.125 MG TABLET, manufactured by ScieGen Pharmaceuticals Inc., is $0.0394 per EA (NDC 50228012610), effective Sep 30, 2026.
How has the price of PRAMIPEXOLE 0.125 MG TABLET changed over time?
Over the history we have for it, the NADAC for PRAMIPEXOLE 0.125 MG TABLET has declined 25.2%. It has been tracked across 273 weekly CMS publications since Jul 14, 2021.
What are the highest and lowest recorded NADAC prices for PRAMIPEXOLE 0.125 MG TABLET?
Since Jul 14, 2021, the NADAC for PRAMIPEXOLE 0.125 MG TABLET has ranged from a low of $0.0350 (Nov 20, 2024) to a high of $0.0595 (Jan 12, 2022), with a median of $0.0467 per EA.
Are there cheaper alternatives to PRAMIPEXOLE 0.125 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as PRAMIPEXOLE 0.125 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures PRAMIPEXOLE 0.125 MG TABLET?
PRAMIPEXOLE 0.125 MG TABLET (NDC 50228012610) is labeled by ScieGen Pharmaceuticals Inc., and CMS classifies it as a generic product.